$CYN
Cyngn Inc. Stock $cyn

$cyn Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023065594 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$25.21K	$551.0K
YoY Change
Cost Of Revenue	$42.41K	$462.6K
YoY Change
Gross Profit	-$17.20K	$88.33K	$0.00
YoY Change
Gross Profit Margin	-68.24%	16.03%
Selling, General & Admin	$2.663M	$2.846M	$2.357M
YoY Change	4.34%	20.73%	25.58%
% of Gross Profit		3221.99%
Research & Development	$2.929M	$3.738M	$2.256M
YoY Change	7.46%	65.71%	171.15%
% of Gross Profit		4231.75%
Depreciation & Amortization	$89.63K	$93.04K	$24.33K
YoY Change	111.95%	282.4%	10.37%
% of Gross Profit		105.33%
Operating Expenses	$2.929M	$3.738M	$4.613M
YoY Change	-44.5%	-18.97%	120.33%
Operating Profit	-$5.610M	-$6.495M	-$4.613M
YoY Change	6.28%	40.81%	120.33%
Interest Expense	$32.91K	$18.89K	-$1.610K
YoY Change	603.21%	-1273.29%	-73.34%
% of Operating Profit
Other Income/Expense, Net	$138.2K	$142.0K	$952.00
YoY Change	628.35%	14817.33%	-53.58%
Pretax Income	-$5.472M	-$6.353M	-$4.612M
YoY Change	4.03%	37.76%	26.58%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.472M	-$6.353M	-$4.612M
YoY Change	4.03%	37.76%	120.5%
Net Earnings / Revenue	-21703.74%	-1153.17%
Basic Earnings Per Share	-$0.14	-$0.19	-$0.15
Diluted Earnings Per Share	-$0.14	-$0.19	-$0.15
COMMON SHARES
Basic Shares Outstanding	33.99M shares	33.83M shares	30.71M shares
Diluted Shares Outstanding	37.77M shares	33.79M shares	30.71M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.156M	$12.12M	$32.60M
YoY Change	-70.47%	-62.83%	857.64%
Cash & Equivalents	$3.500M	$3.056M	$5.602M
Short-Term Investments	$4.619M	$9.064M	$27.00M
Other Short-Term Assets	$436.9K	$1.134M	$653.5K
YoY Change	-25.54%	73.56%	34.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$8.593M	$13.25M	$33.26M
YoY Change	-69.54%	-60.15%	754.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.393M	$1.191M	$467.7K
YoY Change	112.85%	154.73%	361.26%
Goodwill
YoY Change
Intangibles	$1.160M	$556.8K	$181.9K
YoY Change	218.25%	206.12%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.958M	$2.302M	$1.293M
YoY Change	93.72%	78.07%	864.37%
TOTAL ASSETS
Total Short-Term Assets	$8.593M	$13.25M	$33.26M
Total Long-Term Assets	$2.958M	$2.302M	$1.293M
Total Assets	$11.55M	$15.56M	$34.55M
YoY Change	-61.15%	-54.97%	758.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$234.4K	$305.4K	$243.5K
YoY Change	-21.64%	25.41%	87.26%
Accrued Expenses	$245.4K	$181.7K	$138.7K
YoY Change	417.85%	31.0%	-40.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$32.61M
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.348M	$1.614M	$1.086M
YoY Change	42.5%	48.63%	188.49%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities			$189.8K
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$189.8K
YoY Change		-100.0%	-88.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.348M	$1.614M	$1.086M
Total Long-Term Liabilities	$0.00	$0.00	$189.8K
Total Liabilities	$1.348M	$1.614M	$1.275M
YoY Change	42.5%	26.52%	-35.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$153.2M	-$147.7M	-$124.9M
YoY Change	17.68%	18.24%
Common Stock	$352.00	$338.00	$336.00
YoY Change	4.45%	0.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.600M	$9.100M
YoY Change	-79.09%
Treasury Stock Shares
Shareholders Equity	$10.20M	$13.94M	$33.27M
YoY Change
Total Liabilities & Shareholders Equity	$11.55M	$15.56M	$34.55M
YoY Change	-61.15%	-54.97%	758.21%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$5.472M	-$6.353M	-$4.612M
YoY Change	4.03%	37.76%	120.5%
Depreciation, Depletion And Amortization	$89.63K	$93.04K	$24.33K
YoY Change	111.95%	282.4%	10.37%
Cash From Operating Activities	-$4.190M	-$4.870M	-$3.602M
YoY Change	-8.84%	35.17%	1.65%
INVESTING ACTIVITIES
Capital Expenditures	$424.4K	$34.04K	-$183.4K
YoY Change	-285.13%	-118.56%	1471.38%
Acquisitions
YoY Change
Other Investing Activities	$4.084M	-$9.820K	-$27.15M
YoY Change	-15.6%	-99.96%
Cash From Investing Activities	$3.659M	-$43.86K	-$27.34M
YoY Change	-20.61%	-99.84%	234149.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.011M	1.230K	18.13M
YoY Change	6023.8%	-99.99%	1906.35%
NET CHANGE
Cash From Operating Activities	-4.190M	-4.870M	-3.602M
Cash From Investing Activities	3.659M	-43.86K	-27.34M
Cash From Financing Activities	1.011M	1.230K	18.13M
Net Change In Cash	480.1K	-4.912M	-12.81M
YoY Change	1529.15%	-61.64%	382.91%
FREE CASH FLOW
Cash From Operating Activities	-$4.190M	-$4.870M	-$3.602M
Capital Expenditures	$424.4K	$34.04K	-$183.4K
Free Cash Flow	-$4.615M	-$4.904M	-$3.419M
YoY Change	5.67%	43.42%	-3.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40932
	dei	Entity Registrant Name EntityRegistrantName	CYNGN INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2007094
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1015 O’Brien Dr
	dei	Entity Address City Or Town EntityAddressCityOrTown	Menlo Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94025
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	924-5905
	dei	Security12b Title Security12bTitle	Common stock, $0.00001
	dei	Trading Symbol TradingSymbol	CYN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33993964	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3055843	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10536273	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	50000	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	9063675	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	12064337	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1134255	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1126137	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	13253773	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	23776747	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1191275	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	884000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	553919	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	371189	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	556778	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	473076	usd
CY2023Q2	us-gaap	Assets Assets	15555745	usd
CY2022Q4	us-gaap	Assets Assets	25505012	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	305403	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	155943	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	751190	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	854920	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	557108	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	376622	usd
CY2023Q2	us-gaap	Liabilities Liabilities	1613701	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1387485	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33830900	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33830900	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33684864	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33684864	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	338	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	337	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	161653902	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	159847229	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147712196	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-135730039	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13942044	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	24117527	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15555745	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25505012	usd
CY2023Q2	us-gaap	Revenues Revenues	550952	usd
	us-gaap	Revenues Revenues	1423752	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	462624	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1079318	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3737818	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2255666	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6767874	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3936811	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2845922	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2357247	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5916841	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4494763	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	7046364	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	4612913	usd
	us-gaap	Costs And Expenses CostsAndExpenses	13764033	usd
	us-gaap	Costs And Expenses CostsAndExpenses	8431574	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6495412	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4612913	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12340281	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8431574	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	18891	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1607	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	65793	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1986	usd
CY2023Q2	us-gaap	Other Income OtherIncome	123122	usd
CY2022Q2	us-gaap	Other Income OtherIncome	2559	usd
	us-gaap	Other Income OtherIncome	292331	usd
	us-gaap	Other Income OtherIncome	2560	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	142013	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	952	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	358124	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	574	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6353399	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4611961	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11982157	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8431000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33794325	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30706235	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33748799	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28682245	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	19037550	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8773	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11989509	usd
CY2022Q2	cyngn	Issuance Of Common Warrants At Fair Value In Connection With The Private Placement IssuanceOfCommonWarrantsAtFairValueInConnectionWithThePrivatePlacement	6132436	usd
CY2022Q2	cyngn	Issuance Of Common Stock And Prefunded Warrants In Connection With The Private Placement Offer IssuanceOfCommonStockAndPrefundedWarrantsInConnectionWithThePrivatePlacementOffer	2662	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	713570	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4611961	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	33272539	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	19420512	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1223	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	873708	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6353399	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13942044	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22247562	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	97658	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11989509	usd
	cyngn	Issuance Of Common Warrants At Fair Value In Connection With The Private Placement IssuanceOfCommonWarrantsAtFairValueInConnectionWithThePrivatePlacement	6132436	usd
	cyngn	Issuance Of Common Stock And Prefunded Warrants In Connection With The Private Placement Offer IssuanceOfCommonStockAndPrefundedWarrantsInConnectionWithThePrivatePlacementOffer	2662	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1233712	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8431000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	33272539	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	24117527	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	8067	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1798607	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11982157	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13942044	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11982157	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8431000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	474990	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	229102	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1798607	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1233712	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	291555	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	473047	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	902512	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	149460	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	131260	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	76756	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	736805	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10246946	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7002633	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	481777	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	410289	usd
	cyngn	Proceed From Sale Of Other Productive Assets ProceedFromSaleOfOtherProductiveAssets	101991	usd
	cyngn	Proceed From Sale Of Other Productive Assets ProceedFromSaleOfOtherProductiveAssets	153550	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17011782	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	27000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	20304000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2708450	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27563839	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	18121945	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2662	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8066	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	97658	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8066	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18222265	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7530430	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-16344207	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10586273	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21995981	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3055843	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5651774	usd
CY2023Q2	us-gaap	Cash Cash	3055843	usd
CY2022Q2	us-gaap	Cash Cash	5601774	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	50000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3055843	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5651774	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	464929	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	824292	usd
	cyngn	Change In Deferred Rent Associated With Asc842 ChangeInDeferredRentAssociatedWithASC842	58676	usd
	cyngn	Acquisition Property And Equipment Included In Accounts Payable And Accrued Expenses AcquisitionPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	22185	usd
	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	Pursuant to the Purchase Agreement, the Company sold (i) 3,790,322 shares of its Common Stock together with Common Warrants to purchase up to 3,790,322 shares of Common Stock, and (ii) 2,661,291 Pre-Funded Warrants with each Pre-Funded Warrant exercisable for one share of Common Stock, together with Common Warrants to purchase up to 2,661,291 shares of Common Stock.
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.09
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.98
	cyngn	Exercisable Expires Term ExercisableExpiresTerm	P5Y
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	12000000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	8400000	usd
CY2023Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	147700000	usd
CY2022Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	135700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	10200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	7000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments include but are not limited to warrants and share-based compensation. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, which is placed with high-credit-quality financial institutions and at times exceeds federally insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash maintained with domestic financial institutions generally exceed the Federal Deposit Insurance Corporation insurable limit. To date, the Company has not experienced any losses on its deposits of cash. Cyngn invests in U.S. Treasury securities and carries these at amortized cost and recognizes gains and losses when realized.</p>
CY2023Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	3100000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	10500000	usd
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P15Y
CY2022Q2	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	100000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P15Y
CY2023Q2	us-gaap	Public Utilities Property Plant And Equipment Construction Work In Progress PublicUtilitiesPropertyPlantAndEquipmentConstructionWorkInProgress	203133	usd
CY2022Q4	us-gaap	Public Utilities Property Plant And Equipment Construction Work In Progress PublicUtilitiesPropertyPlantAndEquipmentConstructionWorkInProgress	359289	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1888861	usd
CY2022Q4	cyngn	Percentage Of Accounts Receivable PercentageOfAccountsReceivable	0	pure
CY2023Q2	us-gaap	Amount Of Deferred Costs Related To Long Term Contracts AmountOfDeferredCostsRelatedToLongTermContracts	0	usd
CY2022Q4	us-gaap	Amount Of Deferred Costs Related To Long Term Contracts AmountOfDeferredCostsRelatedToLongTermContracts	100000	usd
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue	9100000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	12100000	usd
CY2023Q2	cyngn	Automobiles Automobiles	399087	usd
CY2022Q4	cyngn	Automobiles Automobiles	397816	usd
CY2023Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	176402	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	176402	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	423665	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	380457	usd
CY2023Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	686574	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	93120	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1407084	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	697586	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	523084	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	1191275	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	884000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	93039	usd
CY2022Q2	us-gaap	Depreciation Depreciation	24330	usd
	us-gaap	Depreciation Depreciation	174502	usd
	us-gaap	Depreciation Depreciation	45405	usd
CY2023Q2	cyngn	Credit Card Payable CreditCardPayable	10873	usd
CY2022Q4	cyngn	Credit Card Payable CreditCardPayable	5194	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	181742	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	283118	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	558575	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	566608	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	751190	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	854920	usd
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	48000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	568445	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11337	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	557108	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0184	pure
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	149261	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	157869	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	291847	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	235968	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	144177	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	133998	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	282199	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	181110	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	610813	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-54035	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	556778	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	508821	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-35745	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	473076	usd
CY2023Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	9742	usd
CY2022Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1720	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	18289	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2587	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33830900	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33830900	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33684864	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33684864	shares
CY2023Q2	cyngn	Warrants Outstanding WarrantsOutstanding	6591613	shares
	cyngn	Fair Value FairValue	6302833	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6353399	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4611961	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	33794325	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	30706235	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11982157	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8431000	usd
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	33748799	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	28682245	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
	cyngn	Fair Value Is Recognized FairValueIsRecognized	The resulting fair value is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award. The Company has elected to recognize forfeitures as they occur. Stock options generally vest over four years and have a contractual term of ten years.
	cyngn	Common Stock Shares Issurance CommonStockSharesIssurance	2200000	shares
CY2022	cyngn	Common Stock Shares Issurance CommonStockSharesIssurance	3600000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14715110	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.23
CY2022Q4	cyngn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M2D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2571013	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2341000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.03
	cyngn	Stocks Issued During Period Shares Stock Options Exercised StocksIssuedDuringPeriodSharesStockOptionsExercised	23750	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.34
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15523	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1066045	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.75
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15966315	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.17
CY2023Q2	cyngn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7548582	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	15966315	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.17
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7548582	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	7527990	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.88
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	5823641	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	216036	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.52
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	108000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	122286	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	5.52
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	201750	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.13
	cyngn	Weighted Average Per Share Grantdate Fair Value Of Options Granted WeightedAveragePerShareGrantdateFairValueOfOptionsGranted	0.56
	cyngn	Weighted Average Per Share Grantdate Fair Value Of Options Granted WeightedAveragePerShareGrantdateFairValueOfOptionsGranted	0.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0361	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0249	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5272	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3623	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	cyngn	Stockbased Compensation Expense From Stock Options StockbasedCompensationExpenseFromStockOptions	873707	usd
CY2022Q2	cyngn	Stockbased Compensation Expense From Stock Options StockbasedCompensationExpenseFromStockOptions	713570	usd
	cyngn	Stockbased Compensation Expense From Stock Options StockbasedCompensationExpenseFromStockOptions	1798607	usd
	cyngn	Stockbased Compensation Expense From Stock Options StockbasedCompensationExpenseFromStockOptions	1233712	usd
	us-gaap	Present Value Of Future Insurance Profits Weighted Average Amortization Period PresentValueOfFutureInsuranceProfitsWeightedAverageAmortizationPeriod	P3Y1M6D
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2022Q2	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	cyngn	Change In Deferred Rent Associated With Asc842 ChangeInDeferredRentAssociatedWithASC842		usd
	cyngn	Acquisition Property And Equipment Included In Accounts Payable And Accrued Expenses AcquisitionPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	30706235	shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	33794325	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	28682245	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	33748799	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2023Q2	cyngn	Aggregate Intrinsic Value Granted AggregateIntrinsicValueGranted		usd
CY2023Q2	cyngn	Aggregate Intrinsic Value Cancelledforfeited AggregateIntrinsicValueCancelledforfeited		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001874097

Files In Submission

Name	View Source	Status
0001213900-23-065594-index-headers.html	Edgar Link	pending
0001213900-23-065594-index.html	Edgar Link	pending
0001213900-23-065594.txt	Edgar Link	pending
0001213900-23-065594-xbrl.zip	Edgar Link	pending
cyngn-20230630.xsd	Edgar Link	pending
f10q0623ex31-1_cyngn.htm	Edgar Link	pending
f10q0623ex31-2_cyngn.htm	Edgar Link	pending
f10q0623ex32-1_cyngn.htm	Edgar Link	pending
f10q0623_cyngn.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
cyngn-20230630_cal.xml	Edgar Link	unprocessable
cyngn-20230630_def.xml	Edgar Link	unprocessable
cyngn-20230630_lab.xml	Edgar Link	unprocessable
cyngn-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0623_cyngn_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYN
Cyngn Inc. Stock $cyn

2023 Q3 Form 10-Q Financial Statement

#000121390023065594 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYN Cyngn Inc. Stock $cyn

2023 Q3 Form 10-Q Financial Statement

#000121390023065594 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYN
Cyngn Inc. Stock $cyn